Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

This is read by an automated voice. Please report any issues or inconsistencies here. Ozempic, Zepbound, and Wegovy are now household names. And as these GLP-1 medications have exploded in popularity, ...

The World Health Organization (WHO) has finally made its recommendations on using glucagon-like peptide-1 (GLP-1) therapeutics for weight loss, though it remains to be seen whether it changes their ...

GLP-1 drugs like Ozempic and Mounjaro have significant health benefits for type 1 diabetes, including weight loss, despite ...

Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health. For the first time ever, the World Health Organization has ...

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

GLP-1 drugs for pets could be the next frontier for the blockbuster weight loss and diabetes drugs. By Emily Anthes In just a few short years, new diabetes and weight loss drugs like Ozempic, Wegovy ...

Questions surround their effects on brain health, pregnancy or long-term use. MIT Technology Review Explains: Let our writers untangle the complex, messy world of technology to help you understand ...

C&EN’s award-winning podcast Inflection Point leans on our 100-year archive to trace headline topics in science today back to their disparate and surprising roots. In each episode, we explore three ...